News
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Total net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments$32.6 million cash balance at September 30, 2025Company remains on track to launch EXXUA™...
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Aytu BioPharma Announces Patent Term Extension for EXXUA™
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Aytu BioPharma to Present at Upcoming October 2025 Conferences
DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Aytu BioPharma to Present at Upcoming September 2025 Conferences
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for...
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA™
Full year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone)...
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for...
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA™
DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA™
Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities allow for added working capital flexibility as...